Novo Nordisk must stay ready to increase Wegovy sales, says CFO
![Group CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13575993.ece/ALTERNATES/schema-16_9/doc7ix5d425ark1dbqpp3pd.jpg)
Novo Nordisk's latest issue with meeting patient demand for obesity drug Wegovy arose just one week after its sales force were called to a meeting in Las Vegas to prepare a large-scale sales campaign.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
US manufacturer cannot supply Wegovy injector pen syringes
For subscribers